Searchable abstracts of presentations at key conferences in endocrinology

ea0050cmw5.3 | Workshop 5: How do I. . . (2) | SFEBES2017

How do I ... approach CVS surveillance in a patient with Turner Syndrome

Gravholt Claus H

New international clinical guidelines have just been published, based on an international effort that started with exploratory meetings in 2014 in both Europe and the USA, and culminated with a Consensus Meeting held in Cincinnati, Ohio, USA in July 2016. These guidelines were initiated and developed by ESE in Europe, and by PES in USA, with important contributions from ESHRE, Endocrine Society, ESC, AHA, Society for Endocrinology, and ESPE.Morbidity and...

ea0050cmw5.3 | Workshop 5: How do I. . . (2) | SFEBES2017

How do I ... approach CVS surveillance in a patient with Turner Syndrome

Gravholt Claus H

New international clinical guidelines have just been published, based on an international effort that started with exploratory meetings in 2014 in both Europe and the USA, and culminated with a Consensus Meeting held in Cincinnati, Ohio, USA in July 2016. These guidelines were initiated and developed by ESE in Europe, and by PES in USA, with important contributions from ESHRE, Endocrine Society, ESC, AHA, Society for Endocrinology, and ESPE.Morbidity and...

ea0063mte8 | (1) | ECE2019

Comorbidities in Turner Syndrome

Gravholt Claus H.

Treatment with growth hormone (GH) during childhood and adolescence allows a considerable gain in adult height. SHOX deficiency explains some of the phenotypic characteristics in TS, principally short stature. Puberty has to be induced in most cases, and female sex hormone replacement therapy should continue during adult years. These issues are normally dealt with by the paediatrician, but once a TS female enters adulthood it is less clear who should be the primary care giver....

ea0049gs1.1 | Guided session 1 | ECE2017

New international clinical practice guidelines for the care of girls and women with turner syndrome

Gravholt Claus H

Turner syndrome (TS) affects 25–50 per 100 000 females and can involve multiple organs through all stages of life, necessitating a multidisciplinary approach to care. Previous guidelines have highlighted this, but numerous important advances have been noted since their publication. These advances cover all specialty fields involved in the care of girls and women with TS. This new international guideline is based on an international effort that started with exploratory mee...

ea0032s13.2 | Hormonal treatment in transition of patients with rare diseases (Supported by the <ulink url="http://www.eje-online.org/"><emphasis role="italic">European Journal of Endocrinology</emphasis></ulink>) | ECE2013

Transition of females with Turner syndrome

Gravholt Claus H

Treatment with GH during childhood and adolescence allows a considerable gain in adult height. SHOX deficiency explains some of the phenotypic characteristics in TS, principally short stature. Puberty has to be induced in most cases, and female sex hormone replacement therapy should continue during adult years. These issues are normally dealt with by the paediatrician, but once a TS female enters adulthood it is less clear who should be the primary care giver. Morbidity and mo...

ea0014p616 | (1) | ECE2007

Protein metabolism in a model of premature ovarian failure, Turner syndrome, and the impact of hormone replacement therapy

Gravholt Claus H , Riis Anne-Lene , Christiansen Jens Sandahl

Background: Several studies have documented an altered body composition in Turner syndrome (TS), a model of premature ovarian failure. Body fat is increased and muscle mass is decreased. The ovarian failure necessitates substitution with female hormone replacement therapy (HRT) for a number of years, and HRT induces favourable changes in body composition with a decrease in body fat and an increase in fat free mass. It is unknown how HRT affects protein metabolism.<p class=...

ea0081oc12.4 | Oral Communications 12: Reproductive and Developmental Endocrinology | ECE2022

Sex-chromosome dosage effects on circular RNA: A circular transcriptome-wide study of Turner and Klinefelter syndrome across different tissues

Bruun Johannsen Emma , Just Jesper , Viuff Mette , Fedder Jens , Skakkebaek Anne , Gravholt Claus H

Background: Turner syndrome (45,X; TS) and Klinefelter syndrome (47,XXY; KS) present with a range of clinical features due to copy number aberrations of the X chromosome. The underlying genetics of these syndromes have revealed karyotype-dependent transcription and methylation patterns, and implicated genes that escape X chromosome inactivation (XCI). Alterations in the expression pattern of non-coding RNAs has previously been reported in TS and KS, yet the landscape of circul...

ea0063oc14.5 | Sex Hormones | ECE2019

The pattern of cancer occurrence in Turner syndrome

Viuff Mette , Berglund Agnethe , Juul Svend , Stochholm Kirstine , Gravholt Claus H

Background: Studies have shown that the overall risk of cancer is not increased in Turner syndrome (TS). However, the pattern of cancer occurrence may be different than in the background population.Aim: To describe the cancer morbidity pattern in TS.Design: Nationwide epidemiological study using Danish registries on morbidity.Methods: 1,156 Females with TS diagnosed during 1960–2014 were identified using...

ea0073pep4.8 | Presented ePosters 4: Reproductive and Developmental Endocrinology | ECE2021

Current clinical practice of prenatal dexamethasone treatment in at risk pregnancies for classic 21‑hydroxylase deficiency in Europe

Nowotny Hanna F. , Blankenstein Oliver , Neumann Uta , Ahmed S. Faisal , Allen Stephanie , Baronio Federico , Battelino Tadej , Bertherat Jérôme , Bonomi Marco , de la Perrière Aude Brac , Tardy Véronique , Brucker Sara , Cappa Marco , Chanson Philippe , Bouvattier Claire , Colao Annamaria , Cools Martine , Davies Justin , Fenske Wiebke K. , Ghigo Ezio , Højbjerg Gravholt Claus , Hübner Angela , Husebye Eystein Sverre , Juul Anders , Kiefer Florian W. , Léger Juliane , Meyer Gesine , Phylactou Leonidas A. , Rohayem Julia , Russo Gianni , Scaroni Carla , Touraine Philippe , Unger Nicole , Hedi L. Claahsen-van der Grinten , Vojtková Jarmila , Yeste Diego , Günther Dörr Helmut , Lajic Svetlana , Reisch Nicole

BackgroundPrenatal dexamethasone treatment (Pdex) has been used since the 1980s to prevent virilization in female offspring suspected to have congenital adrenal hyperplasia (CAH). However, due to lack of strong evidence for its best practice as well as limited data regarding longterm adverse effects, use of dex is highly controversial. This study reveals the current medical practice regarding Pdex in female fetuses at risk of CAH due to 21hydroxylase def...